Riskpilot← Back to searchSign inGet full accessPROVECTUS PHARMA NORDIC AS
ASActiveOrg 828035762Slogumveien 99, 2015 LeirsundRetail sale of other food · NACE 4727Est. 20212 employeeswww.provectuspharma.no
Revenue 2024
NOK 20,2M
-15% vs 2023
EBITDA margin
2.1%
-33% vs 2023
Equity ratio
23.5%
Financial strength
Net profit 2024
NOK 249K
+6% vs 2023
| Revenue | NOK 20,2M | -15% |
| EBITDA | NOK 429K | -33% |
| Net profit | NOK 249K | +6% |
| Total assets | NOK 9,2M | +6% |
| Equity | NOK 2,2M | +13% |
| Employees | 2 | — |
Legal name
PROVECTUS PHARMA NORDIC AS
Org number
828035762
Legal form
Aksjeselskap
NACE code
4727 · Retail sale of other food
Founded
1. november 2021
Share capital
NOK 120 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg. Styrets leder alene.
Company purpose
Engros-, postordre- og internettsalg med helsekost/helserelaterte produkter. Import/engroshandel med parfyme og kosmetikk. Engroshandel med spesialisert utvalg av nærings- og nytelsesmidler.
Address
Slogumveien 99, 2015 Leirsund
Website
www.provectuspharma.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 4 664 | 36 075 | 23 645 | 20 201 |
| Staff expenses | −185 | −1 493 | −527 | −1 998 |
| EBITDA | 612 | 3 019 | 645 | 429 |
| Depreciation & amort. | −0 | −29 | −42 | −43 |
| EBIT | 612 | 2 990 | 603 | 386 |
| Net financials | −305 | −1 299 | −104 | −130 |
| Profit before tax | 306 | 1 691 | 500 | 256 |
| Tax | 69 | 375 | 265 | 8 |
| Net profit | 238 | 1 316 | 234 | 249 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 15 837 | 7 000 | 8 639 | 9 154 |
| Equity | 352 | 1 668 | 1 903 | 2 152 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 15 485 | 5 332 | 6 736 | 7 003 |
| Total debt | 15 485 | 5 332 | 6 736 | 7 003 |
EBITDA margin
2.1%
This company
15.8%
Market median
-87% vs market
20212024
Equity ratio
23.5%
This company
38.2%
Market median
-38% vs market
20212024
Return on equity
11.6%
This company
18.4%
Market median
+37% vs market
20212024
Net profit margin
1.2%
This company
8.1%
Market median
-85% vs market
20212024
Asset turnover
2.21×
This company
1.12×
Market median
+97% vs market
20212024
Debt / equity
3.25×
This company
0.62×
Market median
-424% vs market
20212024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-10-11 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Chairman | 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Slinning Holding As
PROVECTUS PHARMA NORDIC AS Board members of PROVECTUS PHARMA NORDIC AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ronny Licina Steng | Board of Directors | 0 companies |
| Jarle André Nummestad | Board of Directors | 0 companies |
| Eddy Licina Steng | Chairman | 0 companies |